Results 1 to 10 of about 7,663 (213)

Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science. [PDF]

Clin Transl Sci
ABSTRACT Major depressive disorder (MDD) imposes a substantial burden worldwide, with treatment‐resistant depression (TRD) and major depressive disorder with acute suicidal ideation or behavior (MDSI) representing two of the most severe clinical challenges.
van Hoogdalem MW, Fu DJ, Drevets WC, Zannikos PN.   +3 more
europepmc   +2 more sources

Clinical applications of esketamine: Current status and future perspectives [PDF]

Journal of International Medical Research
Ketamine, a dissociative anesthetic, has been extensively used in clinical anesthesia and sedation. However, its use in general anesthesia is gradually declining because of numerous adverse effects.
Hui Li, Jingjing Deng, Tao Liu, Yuenong Zhang   +3 more
doaj   +2 more sources

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series [PDF]

European Journal of Psychotraumatology
Background: Posttraumatic stress disorder (PTSD) is a severe and frequent affection that is highly comorbid to major depressive disorder. Comorbid PTSD and depression increase the risk of treatment-resistant depression (TRD), with a high risk of ...
Maud Rothärmel, Lila Mekaoui, François Kazour, Morgane Herrero, Eva-Maria Beetz-Lobono, Aiste Lengvenyte, Jérôme Holtzmann, Philippe Raynaud, Macarena Cuenca, Samuel Bulteau, Pierre De Maricourt, Thomas Husson, Emilie Olié, Bénédicte Gohier, Anne Sauvaget, Raphaël Gaillard, Raphaëlle Richieri, David Szekely, Ludovic Samalin, Olivier Guillin, Virginie Moulier, Wissam El-Hage, Andrew Laurin, Lucie Berkovitch   +23 more
doaj   +2 more sources

Esketamine hydrochloride in the management of moderate-to-severe depressive symptoms in patients undergoing multiple wound repair surgeries: A multi-centre randomized, double-blind, placebo-controlled trial. [PDF]

Clin Transl Med
1. Multi‐centre, double‐blind, randomized controlled trial. 2. No esketamine‐related adverse events within 30 days postoperatively. 3. Esketamine group showed higher MADRS response and remission rates. Abstract Introduction Patients undergoing multiple wound repair surgeries often develop moderate‐to‐severe anxiety and depression.
Yu X, Shen T, Zhang T, Bao R, Guo Z, Feng Z, Tong L, Zhang X, Ran M, Sun G, Mi W, Lou J, Fu Q.   +12 more
europepmc   +2 more sources

Global Trends and Hotspots in Esketamine Research: A Bibliometric Analysis of Past and Estimation of Future Trends

Drug Design, Development and Therapy, 2022
Xiang Li,1 Ping Xiang,2 Jianfen Liang,1 Yifan Deng,1 Jingyi Du1 1Department of Anesthesiology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, People’s Republic of China; 2Department of Medical Quality Management, Nanfang ...
Li X, Xiang P, Liang J, Deng Y, Du J
doaj   +2 more sources

The 90% effective dose (ED90) of esketamine for inhibiting responses to intraoperative motor stimulation during ambulatory hysteroscopy: a biased-coin up-and-down sequential allocation trial [PDF]

BMC Anesthesiology
Background Esketamine and remimazolam co-administration presents a viable opioid-free anesthetic alternative for outpatient hysteroscopy. This study was designed to ascertain the ED90 of esketamine for inhibiting intraoperative movement responses in ...
Ruiqi Zhang, Chen Wang, Lin Wang, Wenyue Kang, Zhihua Wang   +4 more
doaj   +2 more sources

Dose-dependent effects of esketamine on the prevention of propofol-induced injection pain: a randomized controlled trial [PDF]

BMC Anesthesiology
Background In our previous study, we showed that a low dose of esketamine could alleviate propofol-induced injection pain during general anesthesia induction. However, the dose-response relationship of esketamine remains unclear.
Danyun Fu, Yilei Shen, Hongyan Xiao, Jie Jia   +3 more
doaj   +2 more sources

Intermittent versus continuous esketamine infusions for long-term pain modulation in complex regional pain syndrome: protocol of a randomized controlled non-inferiority study (KetCRPS-2)

BMC Musculoskeletal Disorders, 2023
Background Complex regional pain syndrome (CRPS) is a chronic pain condition of an extremity. While achieving pain relief in CRPS is challenging, esketamine infusions can accomplish pain relief for several weeks post-infusion in a subgroup of CRPS ...
Thomas J. P. Mangnus, Maaike Dirckx, Krishna D. Bharwani, Sara J. Baart, Theodora A. M. Siepman, Ken Redekop, Willem A. Dik, Cecile C. de Vos, Frank J. P. M. Huygen   +8 more
doaj   +1 more source

Efficacy and safety of esketamine for sedation among patients undergoing gastrointestinal endoscopy: a systematic review and meta-analysis

BMC Anesthesiology, 2023
Background Patients who undergo gastrointestinal endoscopy often require propofol-based sedation combined with analgesics. At present, the efficacy and safety of esketamine as an adjunct to propofol for sedation during endoscopic procedures in patients ...
Xianghong Lian, Yunzhu Lin, Ting Luo, Yang Jing, Hongbo Yuan, Yixin Guo   +5 more
doaj   +1 more source

Midazolam Attenuates Esketamine-Induced Overactive Behaviors in Mice Before the Sedation, but Not During the Recovery

Frontiers in Veterinary Science, 2022
Esketamine showed more potency, more rapid recovery from anesthesia, and less psychotomimetic side effects when compared with ketamine. However, the patients still experience psychotomimetic side effects of esketamine.
Qinjun Chu, Meng Mao, Yafan Bai, Liwei Sun, Dongqing Zhang, Ping Zheng, Xiaogao Jin, Xiaogao Jin, Xiaogao Jin, Xiaogao Jin   +9 more
doaj   +1 more source